Jane Street
ALXO icon

Jane Street’s ALX Oncology ALXO Stock Holding History

Jane Street’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-13,000
Closed -$105K – 9626
2022
Q2 		$105K Buy
+13,000
New +$142K ﹤0.01% 8605
2021
Q4 		– Sell
-9,400
Closed -$694K – 9994
2021
Q3 		$694K Buy
+9,400
New +$627K ﹤0.01% 6655

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Jane Street's ALXO Position: Q2 2026 in Review

Jane Street sold out of ALX Oncology (ALXO) in Q2 2026, closing a stake of 95,101 shares — an estimated $191K sold.

Jane Street first reported a position in ALXO in Q3 2022 and held it in 11 quarters. The position peaked at $660K in Q1 2024. 94 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

  • Jane Street reported no remaining ALX Oncology position as of Q2 2026 after selling out during the quarter.
  • Jane Street sold 95,101 ALX Oncology shares in Q2 2026, an estimated $191K.
  • Jane Street first reported a position in ALX Oncology in Q3 2022 and held it in 11 quarters.
  • Jane Street's ALX Oncology position peaked at $660K in Q1 2024.
  • 94 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.